# Diane Provencher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/diane-provencher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,493 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 68 |
| i10-index | 240 |
| Last Known Institution | Centre Hospitalier de l’Université de Montréal |
| OpenAlex ID | https://openalex.org/A5020493456 |
| ORCID iD | https://orcid.org/0000-0003-1902-3256 |
| Works | 462 |

## Researcher papers

- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas](https://scholariq.org/papers/i-arid1a-i-mutations-in-endometriosis-associated-ovarian-carcinomas/)
- [Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary](https://scholariq.org/papers/mutation-of-i-foxl2-i-in-granulosa-cell-tumors-of-the-ovary/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group](https://scholariq.org/papers/phase-ii-study-of-temsirolimus-in-women-with-recurrent-or-metastatic-endometrial/)
- [Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I](https://scholariq.org/papers/sentinel-nodes-in-vulvar-cancer-long-term-follow-up-of-the-groningen/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)](https://scholariq.org/papers/molecular-and-clinical-determinants-of-response-and-resistance-to-rucaparib-for/)
- [Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial](https://scholariq.org/papers/niraparib-maintenance-therapy-in-patients-with-recurrent-ovarian-cancer-after-a/)
- [Uterine serous carcinoma](https://scholariq.org/papers/uterine-serous-carcinoma/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Centre Hospitalier de l’Université de Montréal](https://scholariq.org/institutions/centre-hospitalier-de-l-universite-de-montreal/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.